Semax compounding review puts neuropeptide claims against the federal record

What happened

Semax-related bulk drug substances were reviewed by the FDA’s Pharmacy Compounding Advisory Committee. The meeting agenda identified cerebral ischemia, migraine and trigeminal neuralgia among the uses submitted for consideration.

What the record says

The FDA package evaluated substance identity, chemistry, historical compounding use, effectiveness and safety. For peptide products, those questions include whether the exact active ingredient is consistently named and characterized and whether the route and formulation introduce additional quality risks.

What it does not mean

The committee’s discussion did not make Semax an FDA-approved treatment. Evidence or use outside the United States does not automatically satisfy the legal and scientific standards governing domestic compounded drugs.

Why it matters

Semax illustrates a recurring problem in peptide coverage: biological plausibility and international experience can be informative, but neither substitutes for a clearly defined product and a clinical evidence package relevant to the claim being made.